Pressure BioSciences Novel
UST™ Platform Delivers Breakthrough
Nanoemulsion Processing for One of the
World's Most Potent Antioxidants -
Astaxanthin
Unprecedentedly Tiny,
Uniform, and Stable Nanoemulsified Oil Droplets Containing
Astaxanthin
Expected to Significantly Increase
Oral and Topical Absorption of this Antioxidant 6,000x More
Powerful Than Vitamin C
South Easton, MA, July 1, 2021 -- InvestorsHub NewsWire --
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the
development and sale of broadly enabling, pressure-based
instruments, consumables, and platform technology solutions to the
worldwide biotechnology, biotherapeutics, cosmeceuticals,
nutraceuticals, and food & beverage industries, today announced
the application of its Ultra Shear Technology™ ("UST™") platform
for the development of more potent formulations of wide-ranging
nutraceuticals of high therapeutic value, allowing for more
controlled dosing and opportunities for lower cost solutions for
both manufacturers and consumers. Specifically, the Company
reported breakthrough results in processing one of the most
powerful antioxidants known to science, astaxanthin ("AsX"), in
extremely fine and uniform, monodisperse nanoemulsions of oil in
water – critically important for fast and efficient absorption by
the water-based biochemistry of humans and
animals.
Astaxanthin is a natural red pigment produced by the
microalgae Haematococcus
pluvialis. It is responsible for the red coloration of krill and
other crustaceans, and in turn, the familiar coloration of salmon
and flamingos which feed on them.
As an antioxidant, AsX is 6000 times more powerful than vitamin
C, 800 times more powerful than CoQ10, and 100 times more powerful
than vitamin E [1]. In
clinical studies, AsX has been shown to neutralize free radicals,
greatly reducing oxidative stress [2], enhance natural
immune response [3], improve muscle
endurance and exercise performance [4], support
cardiovascular, neural/cognitive and ocular health [5, 6, 7], protect skin
against UV damage and premature aging [8], favorably
modulate specific cell signaling pathways involved in cancer cell
death [9], and even
improve sperm motility in male infertility. Recent
studies have suggested that AsX may help alleviate progression of
COVID-19 into severe cytokine storm condition [10,11]. Further,
AsX can cross the blood–brain barrier and has been shown to
increase gene expression of several proteins known to be involved
in injured brain recovery [12].
It is particularly important for antioxidants be water-soluble,
allowing them to circulate freely through the blood. However,
because AsX is oil-based and intrinsically water-insoluble,
oral/gastrointestinal and topical absorption of AsX is typically
less than 10%, unless it is effectively solubilized in dietary fats
or provided in a lipid-based formulation [13]. Even
then, AsX in oil is typically delivered in large droplets that pass
through the body with very low overall absorption
efficiency.
Gary B. Smejkal, Senior Research Scientist at PBI, explained the
breakthrough achieved by the Company: "Nanoemulsions produced by
PBI's UST platform encapsulate AsX in extremely small oil droplets
ranging in size from 30-60 nm in diameter [14]. Because
these particles are so small, they do not scatter light and thus
appear as clear ruby red liquids that disperse freely in water or
other clear beverages. The enhanced
oral bioavailability of AsX corresponding to droplet size
reduction is well-established
and has been published
[15].
Mr. Smejkal continued: "Our initial stability studies have
already shown that UST-processed AsX nanoemulsions are stable for
at least four months at room temperature without any measurable
change in oil droplet size, coalescence, or phase separation.
We used AsX as a model compound to demonstrate the power of our UST
platform technology. Our approach will be readily suitable to
prepare nanoemulsions of other carotenoids and a wide range of
fat-soluble vitamins and dietary supplements. We believe that the
implications of PBI's UST platform for AsX and for a multitude of
other oil-soluble nutraceuticals will undoubtedly be dramatic in
the marketplace."
Mr. Richard T. Schumacher, President & CEO of
PBI, commented: "The global astaxanthin market size was estimated
at USD 1.0 billion in 2019 [16]. PBI is laser-focused on exploring the opportunities
for our UST platform to profoundly alter the effectiveness and
competitiveness of a great number of lucrative nutraceutical
products. We have already begun discussions with prospective
partners worldwide who are interested in using UST for production
and commercialization of astaxanthin and other nutraceutical
nanoemulsions. We remain optimistic that we will meet our
stated goal of releasing our initial UST-based instrument to the
market before the end of 2021. As previously announced, we intend
to make this system available through a lease/royalty business
model."
About
Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO)
is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions
safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the "BaroFold" technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward Looking Statements
This
press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
For more
information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.
Press
Contacts:
Richard T. Schumacher, President & CEO (508) 230-1828
(T)
Jeffrey N. Peterson, Chairman of the Board (650) 812-8121
(T)
Alexander V. Lazarev, Chief Science Officer (508) 230-1828 (T)
Grafico Azioni Pressure Biosciences (CE) (USOTC:PBIO)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Pressure Biosciences (CE) (USOTC:PBIO)
Storico
Da Gen 2024 a Gen 2025
